Trials / Completed
CompletedNCT00144508
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)
An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 306 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to receive either MRA or conventional DMARDs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRA (Tocilizumab) | 8mg /kg /4week for 52 weeks |
| OTHER | current treatment | continue current treatment |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2004-05-01
- Completion
- 2006-02-01
- First posted
- 2005-09-05
- Last updated
- 2009-02-02
Source: ClinicalTrials.gov record NCT00144508. Inclusion in this directory is not an endorsement.